



**Certificate of Approval of a Prospectus
pursuant to The Prospectus Regulations 2005**

To:

**COMMISSION BANCAIRE, FINANCIERE ET DES ASSURANCES (BELGIUM)
AUTORITE DES MARCHES FINANCIERS (FRANCE)
BUNDESANSTALT FUR FINANZDIENSTLEISTUNGSaufICHT (BAFIN) (GERMANY)
CENTRAL BANK OF IRELAND (IRELAND)
COMMISSIONE NAZIONALE PER LE SOCIETA E LA BORSA (ITALY)
AUTORITEIT FINANCIERE MARKTEN (AFM) (THE NETHERLANDS)
POLISH FINANCIAL SUPERVISION AUTHORITY (POLAND)
COMISSAO DO MERCADO DE VALORES MOBILIARIOS (PORTUGAL)
COMISION NACIONAL DEL MERCADO DE VALORES (SPAIN)**

From:

**The Financial Conduct Authority
25 The North Colonnade, Canary Wharf, London E14 5HS, United Kingdom**

We hereby certify that the Single Prospectus detailed below has been drawn up in accordance with Directive 2003/71/EC as amended by the Directive 2010/73/EU or national law transposing the Directive and was approved by the FCA on 15th June 2017.

Name of Issuer: Abbott Laboratories
Registered Office/Seat: United States
Type of Securities: Prospectus for Employee Share Purchase Plan Offers to Employees
Guarantor (if any):
Annexes: N/A
National Prospectus Identifier: SUP02963

We have authorised, in accordance with Article 8 of Directive 2003/71/EC as amended by the Directive 2010/73/EU or national law transposing Directive 2003/71/EC as amended, the omission of the information on the following grounds: **No omission**

Attachments:

- 1. Single Prospectus dated 15th June 2017**

**Financial Conduct Authority
Document Approved
Date: 20/6/17
Signed: [Signature]**